Cargando…

Antigen Specific Humoral and Cellular Immunity Following SARS-CoV-2 Vaccination in ANCA-Associated Vasculitis Patients Receiving B-Cell Depleting Therapy

Humoral vaccine responses are known to be suboptimal in patients receiving B-cell targeted therapy, and little is known about vaccine induced T-cell immunity in these patients. In this study, we characterized humoral and cellular antigen-specific anti-SARS-CoV2 responses following COVID-19 vaccinati...

Descripción completa

Detalles Bibliográficos
Autores principales: Marty, Paige K., Van Keulen, Virginia P., Erskine, Courtney L., Shah, Maleeha, Hummel, Amber, Stachowitz, Michael, Fatis, Samantha, Granger, Dane, Block, Matthew S., Duarte-García, Alí, Warrington, Kenneth J., Theel, Elitza S., Zhou, Xian, Zeng, Hu, Specks, Ulrich, Escalante, Patricio, Peikert, Tobias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8831839/
https://www.ncbi.nlm.nih.gov/pubmed/35154159
http://dx.doi.org/10.3389/fimmu.2022.834981
_version_ 1784648592650141696
author Marty, Paige K.
Van Keulen, Virginia P.
Erskine, Courtney L.
Shah, Maleeha
Hummel, Amber
Stachowitz, Michael
Fatis, Samantha
Granger, Dane
Block, Matthew S.
Duarte-García, Alí
Warrington, Kenneth J.
Theel, Elitza S.
Zhou, Xian
Zeng, Hu
Specks, Ulrich
Escalante, Patricio
Peikert, Tobias
author_facet Marty, Paige K.
Van Keulen, Virginia P.
Erskine, Courtney L.
Shah, Maleeha
Hummel, Amber
Stachowitz, Michael
Fatis, Samantha
Granger, Dane
Block, Matthew S.
Duarte-García, Alí
Warrington, Kenneth J.
Theel, Elitza S.
Zhou, Xian
Zeng, Hu
Specks, Ulrich
Escalante, Patricio
Peikert, Tobias
author_sort Marty, Paige K.
collection PubMed
description Humoral vaccine responses are known to be suboptimal in patients receiving B-cell targeted therapy, and little is known about vaccine induced T-cell immunity in these patients. In this study, we characterized humoral and cellular antigen-specific anti-SARS-CoV2 responses following COVID-19 vaccination in patients with ANCA-associated vasculitis (AAV) receiving anti-CD20 therapy, who were either B-cell depleted, or B-cell recovered at the time of vaccination and in normal control subjects. SARS-CoV-2 anti-spike (S) and anti-nucleocapsid (NC) antibodies were measured using electrochemiluminescence immunoassays, while SARS-CoV-2 specific T-cell responses to S glycoprotein subunits 1 (S1) and 2 (S2) and receptor binding domain peptide pools were measured using interferon-gamma enzyme-linked immunosorbent spot (ELISPOT) assays. In total, 26 recently vaccinated subjects were studied. Despite the lack of a measurable humoral immune response, B-cell depleted patients mounted a similar vaccine induced antigen-specific T-cell response compared to B-cell recovered patients and normal controls. Our data indicate that to assure a humoral response in patients receiving anti-CD20 therapy, SARS-CoV-2 vaccination should ideally be delayed until B-cell recovery (CD-20 positive B-cells > 10/μl). Nevertheless, SARS-CoV-2 vaccination elicits robust, potentially protective cellular immune responses in these subjects. Further research to characterize the durability and protective effect of vaccine-induced anti-SARS-CoV-2 specific T-cell immunity are needed.
format Online
Article
Text
id pubmed-8831839
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-88318392022-02-12 Antigen Specific Humoral and Cellular Immunity Following SARS-CoV-2 Vaccination in ANCA-Associated Vasculitis Patients Receiving B-Cell Depleting Therapy Marty, Paige K. Van Keulen, Virginia P. Erskine, Courtney L. Shah, Maleeha Hummel, Amber Stachowitz, Michael Fatis, Samantha Granger, Dane Block, Matthew S. Duarte-García, Alí Warrington, Kenneth J. Theel, Elitza S. Zhou, Xian Zeng, Hu Specks, Ulrich Escalante, Patricio Peikert, Tobias Front Immunol Immunology Humoral vaccine responses are known to be suboptimal in patients receiving B-cell targeted therapy, and little is known about vaccine induced T-cell immunity in these patients. In this study, we characterized humoral and cellular antigen-specific anti-SARS-CoV2 responses following COVID-19 vaccination in patients with ANCA-associated vasculitis (AAV) receiving anti-CD20 therapy, who were either B-cell depleted, or B-cell recovered at the time of vaccination and in normal control subjects. SARS-CoV-2 anti-spike (S) and anti-nucleocapsid (NC) antibodies were measured using electrochemiluminescence immunoassays, while SARS-CoV-2 specific T-cell responses to S glycoprotein subunits 1 (S1) and 2 (S2) and receptor binding domain peptide pools were measured using interferon-gamma enzyme-linked immunosorbent spot (ELISPOT) assays. In total, 26 recently vaccinated subjects were studied. Despite the lack of a measurable humoral immune response, B-cell depleted patients mounted a similar vaccine induced antigen-specific T-cell response compared to B-cell recovered patients and normal controls. Our data indicate that to assure a humoral response in patients receiving anti-CD20 therapy, SARS-CoV-2 vaccination should ideally be delayed until B-cell recovery (CD-20 positive B-cells > 10/μl). Nevertheless, SARS-CoV-2 vaccination elicits robust, potentially protective cellular immune responses in these subjects. Further research to characterize the durability and protective effect of vaccine-induced anti-SARS-CoV-2 specific T-cell immunity are needed. Frontiers Media S.A. 2022-01-28 /pmc/articles/PMC8831839/ /pubmed/35154159 http://dx.doi.org/10.3389/fimmu.2022.834981 Text en Copyright © 2022 Marty, Van Keulen, Erskine, Shah, Hummel, Stachowitz, Fatis, Granger, Block, Duarte-García, Warrington, Theel, Zhou, Zeng, Specks, Escalante and Peikert https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Marty, Paige K.
Van Keulen, Virginia P.
Erskine, Courtney L.
Shah, Maleeha
Hummel, Amber
Stachowitz, Michael
Fatis, Samantha
Granger, Dane
Block, Matthew S.
Duarte-García, Alí
Warrington, Kenneth J.
Theel, Elitza S.
Zhou, Xian
Zeng, Hu
Specks, Ulrich
Escalante, Patricio
Peikert, Tobias
Antigen Specific Humoral and Cellular Immunity Following SARS-CoV-2 Vaccination in ANCA-Associated Vasculitis Patients Receiving B-Cell Depleting Therapy
title Antigen Specific Humoral and Cellular Immunity Following SARS-CoV-2 Vaccination in ANCA-Associated Vasculitis Patients Receiving B-Cell Depleting Therapy
title_full Antigen Specific Humoral and Cellular Immunity Following SARS-CoV-2 Vaccination in ANCA-Associated Vasculitis Patients Receiving B-Cell Depleting Therapy
title_fullStr Antigen Specific Humoral and Cellular Immunity Following SARS-CoV-2 Vaccination in ANCA-Associated Vasculitis Patients Receiving B-Cell Depleting Therapy
title_full_unstemmed Antigen Specific Humoral and Cellular Immunity Following SARS-CoV-2 Vaccination in ANCA-Associated Vasculitis Patients Receiving B-Cell Depleting Therapy
title_short Antigen Specific Humoral and Cellular Immunity Following SARS-CoV-2 Vaccination in ANCA-Associated Vasculitis Patients Receiving B-Cell Depleting Therapy
title_sort antigen specific humoral and cellular immunity following sars-cov-2 vaccination in anca-associated vasculitis patients receiving b-cell depleting therapy
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8831839/
https://www.ncbi.nlm.nih.gov/pubmed/35154159
http://dx.doi.org/10.3389/fimmu.2022.834981
work_keys_str_mv AT martypaigek antigenspecifichumoralandcellularimmunityfollowingsarscov2vaccinationinancaassociatedvasculitispatientsreceivingbcelldepletingtherapy
AT vankeulenvirginiap antigenspecifichumoralandcellularimmunityfollowingsarscov2vaccinationinancaassociatedvasculitispatientsreceivingbcelldepletingtherapy
AT erskinecourtneyl antigenspecifichumoralandcellularimmunityfollowingsarscov2vaccinationinancaassociatedvasculitispatientsreceivingbcelldepletingtherapy
AT shahmaleeha antigenspecifichumoralandcellularimmunityfollowingsarscov2vaccinationinancaassociatedvasculitispatientsreceivingbcelldepletingtherapy
AT hummelamber antigenspecifichumoralandcellularimmunityfollowingsarscov2vaccinationinancaassociatedvasculitispatientsreceivingbcelldepletingtherapy
AT stachowitzmichael antigenspecifichumoralandcellularimmunityfollowingsarscov2vaccinationinancaassociatedvasculitispatientsreceivingbcelldepletingtherapy
AT fatissamantha antigenspecifichumoralandcellularimmunityfollowingsarscov2vaccinationinancaassociatedvasculitispatientsreceivingbcelldepletingtherapy
AT grangerdane antigenspecifichumoralandcellularimmunityfollowingsarscov2vaccinationinancaassociatedvasculitispatientsreceivingbcelldepletingtherapy
AT blockmatthews antigenspecifichumoralandcellularimmunityfollowingsarscov2vaccinationinancaassociatedvasculitispatientsreceivingbcelldepletingtherapy
AT duartegarciaali antigenspecifichumoralandcellularimmunityfollowingsarscov2vaccinationinancaassociatedvasculitispatientsreceivingbcelldepletingtherapy
AT warringtonkennethj antigenspecifichumoralandcellularimmunityfollowingsarscov2vaccinationinancaassociatedvasculitispatientsreceivingbcelldepletingtherapy
AT theelelitzas antigenspecifichumoralandcellularimmunityfollowingsarscov2vaccinationinancaassociatedvasculitispatientsreceivingbcelldepletingtherapy
AT zhouxian antigenspecifichumoralandcellularimmunityfollowingsarscov2vaccinationinancaassociatedvasculitispatientsreceivingbcelldepletingtherapy
AT zenghu antigenspecifichumoralandcellularimmunityfollowingsarscov2vaccinationinancaassociatedvasculitispatientsreceivingbcelldepletingtherapy
AT specksulrich antigenspecifichumoralandcellularimmunityfollowingsarscov2vaccinationinancaassociatedvasculitispatientsreceivingbcelldepletingtherapy
AT escalantepatricio antigenspecifichumoralandcellularimmunityfollowingsarscov2vaccinationinancaassociatedvasculitispatientsreceivingbcelldepletingtherapy
AT peikerttobias antigenspecifichumoralandcellularimmunityfollowingsarscov2vaccinationinancaassociatedvasculitispatientsreceivingbcelldepletingtherapy